About e-Therapeutics (LON:ETX)
e-Therapeutics plc is a United Kingdom-based drug discovery and development company. The Company's discovery platform is based on the network of pharmacology and chemical biology. The Company operates in the business segment of drug discovery and development. The Company applies its platform to the discovery of new drug candidates. The therapeutic focus of the Company's discovery activity is in immuno-oncology, addressing drug resistance in targeted cancer therapies and antivirals. The Company generates a range of preclinical stage assets, including ETX1153c, a functionally resistance-less antibiotic; ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule antiTNFα; ETS2400, in Hedgehog pathway inhibition, and ETS5200, which delivers a range of spectrum antivirals. The Company has completed a Phase IIb study of a drug candidate for depressive disorder, ETS6103, as well as Phase I clinical trials in cancer for ETS2101.
Industry, Sector and Symbol
Industry Biotechnology & Medical Research
Trailing P/E Ratio-341.666666666667
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX (0.03)
Return on Equity-40.76%
Return on Assets-37.10%
e-Therapeutics (LON:ETX) Frequently Asked Questions
What is e-Therapeutics' stock symbol?
e-Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "ETX."
Who are some of e-Therapeutics' key competitors?
Some companies that are related to e-Therapeutics include Cleveland BioLabs (CBLI), ReNeuron Group (RENE), OvaScience (OVAS), Caladrius Biosciences (CLBS), AEterna Zentaris (AEZS), Genocea Biosciences (GNCA), Scancell (SCLP), Can Fite Biopharma (CANF), Oncobiologics (ONS), Repros Therapeutics (RPRX), Prana Biotechnology (PRAN), Bio-Path (BPTH), Fibrocell Science (FCSC), OHR Pharmaceutical (OHRP), Burcon NutraScience (BUR), OncoGenex Pharmaceuticals (ACHV), Jaguar Health (JAGX) and Yield10 Bioscience (YTEN).
Who are e-Therapeutics' key executives?
e-Therapeutics' management team includes the folowing people:
- Iain Gladstone Ross, Executive Chairman of the Board (Age 62)
- Raymond John Barlow, Chief Executive Officer, Director (Age 48)
- Steven Medlicott, Chief Financial Officer, Interim Chief Operating Officer, Director (Age 50)
- Trevor M. Jones Ph.D., CBE, Non-Executive Director (Age 74)
- Christine Helen Soden, Non-Executive Director
How do I buy e-Therapeutics stock?
Shares of e-Therapeutics and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is e-Therapeutics' stock price today?
One share of e-Therapeutics stock can currently be purchased for approximately GBX 10.25.
How big of a company is e-Therapeutics?
e-Therapeutics has a market capitalization of £22.17 million.
How can I contact e-Therapeutics?
e-Therapeutics' mailing address is 17 Blenheim Office Park, WITNEY, OX29 8LN, United Kingdom. The company can be reached via phone at +44-1993-880000.
MarketBeat Community Rating for e-Therapeutics (ETX)MarketBeat's community ratings are surveys of what our community members think about e-Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
e-Therapeutics (LON:ETX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for e-Therapeutics (LON:ETX)
No earnings announcements for this company have been tracked by MarketBeat.com
e-Therapeutics (LON:ETX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for e-Therapeutics (LON:ETX)
No dividend announcements for this company have been tracked by MarketBeat.com
e-Therapeutics (LON ETX) Insider Trading and Institutional Ownership History
e-Therapeutics (LON ETX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|1/2/2018||Trevor Mervyn Jones||Insider||Buy||59,460||GBX 9||£5,351.40|
|12/15/2017||Steve Medlicott||Insider||Buy||200,000||GBX 9||£18,000|
|8/22/2017||Iain Gladstone Ross||Insider||Buy||250,000||GBX 11||£27,500|
|7/3/2017||Trevor Mervyn Jones||Insider||Buy||45,364||GBX 1,213||£550,265.32|
|6/1/2017||Steve Medlicott||Insider||Buy||1,000,000||GBX 6||£60,000|
|5/12/2017||Trevor Mervyn Jones||Insider||Buy||59,400||GBX 8||£4,752|
|1/3/2017||Trevor Mervyn Jones||Insider||Buy||36,917||GBX 7||£2,584.19|
|1/21/2015||Steve Medlicott||Insider||Buy||150,000||GBX 25.25||£37,875|
e-Therapeutics (LON ETX) News Headlines
e-Therapeutics (LON:ETX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
e-Therapeutics (LON ETX) Stock Chart for Thursday, January, 18, 2018